Quadruple Medical Therapy for Heart Failure

Interplay of Mineralocorticoid Receptor Antagonists and Empagliflozin in Heart Failure

(2021) João Pedro Ferreira et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trials

(2020) Muthiah Vaduganathan et al.   LANCET

Association of Optimal Implementation of Sodium-Glucose Cotransporter 2 Inhibitor Therapy With Outcome for Patients With Heart Failure

(2020) Nikhil S. Bassi et al.   JAMA Cardiology

SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials

(2020) Faiez Zannad et al.   LANCET

Longitudinal Titration of Medical Therapy for Heart Failure with Reduced Ejection Fraction: CHAMP-HF Registry

(2019) Stephen J. Greene et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Medical Therapy for Heart Failure With Reduced Ejection Fraction

(2018) Stephen J. Greene et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Reduced Risk of Hyperkalemia During Treatment of Heart Failure With Mineralocorticoid Receptor Antagonists by Use of Sacubitril/Valsartan Compared With Enalapril

(2017) Akshay S. Desai et al.   JAMA Cardiology